Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | BLM | P54132 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HBB | P68871 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL136037 | 0.89 | ADA (0.61) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL2028602 | 0.89 | ADA (0.61) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL5064838 | 0.88 | ADA (0.60) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL4259957 | 0.88 | ADA (0.49) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL288325 | 0.87 | ADA (0.58) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL899393 | 0.87 | ADA (0.58) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL8000695 | 0.87 | ADA (0.58) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL3345754 | 0.87 | ADA (0.60) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL6297520 | 0.84 | ADA (0.55) | ADAALDH1A1TP53HTTBLM | |
| SCHEMBL13727118 | 0.84 | ADA (0.55) | ADAALDH1A1TP53HTTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024243-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2024-01-25 | — | — | US | claimed |
| EP-1765844-B1 | PURINE NUCLEOTIDE DERIVATIVES | SOLVELL AS (NO) | 2014-07-30 | — | — | EP | claimed |
| US-8153609-B2 | Purine nucleotide derivatives | LAURAS AS (NO) | 2012-04-10 | — | — | US | claimed |
| US-20110207689-A1 | THE TREATMENT OF HEARING LOSS | AUCKLAND UNISERVICES LIMITED | 2011-08-25 | — | — | US | claimed |
| CN-102159209-A | The treatment of hearing loss | AUCKLAND UNISERVICES LTD | 2011-08-17 | — | — | CN | claimed |
| EP-2328577-A1 | THE TREATMENT OF HEARING LOSS | Auckland UniServices Limited (NZ) | 2011-06-08 | — | — | EP | claimed |
| WO-2010019057-A1 | THE TREATMENT OF HEARING LOSS | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-02-18 | — | — | WO | claimed |
| US-20080293665-A1 | Purine Nucleotide Derivatives | LAURAS AS (NO) | 2008-11-27 | — | — | US | claimed |
| US-20070232560-A1 | Treatment of skin with adenosine or adenosine analog | UNIVERSITY OF MASSACHUSETTS, A MASSACHUSETTS CORPORATION | 2007-10-04 | — | — | US | claimed |
| EP-1765844-A2 | PURINE NUCLEOTIDE DERIVATIVES | Lauras AS (NO) | 2007-03-28 | — | — | EP | claimed |
| US-20060240056-A1 | Treatment of skin with adenosine or adenosine analog | UNIVERSITY OF MASSACHUSETTS, A MASSACHUSETTS CORPORATION | 2006-10-26 | — | — | US | claimed |
| WO-2005123755-A2 | PURINE NUCLEOTIDE DERIVATIVES | LAURAS AS (NO) | 2005-12-29 | — | — | WO | claimed |
| JP-57206396-A | — | — | None | — | — | JP | disclosed |
| US-20240024243-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20210251901-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200121603-A1 | Fine Dry Particulate Adenosine Compositions and Topical Formulations Including the Same | LABORATORY SKIN CARE, INC. | 2020-04-23 | — | — | US | disclosed |
| WO-1994023723-A1 | ADENOSINE RECEPTOR AGONISTS FOR THE PROMOTION OF WOUND HEALING | NEW YORK UNIVERSITY (US) | 1994-10-27 | — | — | WO | disclosed |
| US-5248770-A | Labels such as fluorescent or radioactive compounds | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1993-09-28 | — | — | US | disclosed |
| US-4968672-A | DRUG DELIVERY; DIURETICS, KIDNEY DISORDERS, HYPOTENSIVE AGENTS | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1990-11-06 | — | — | US | disclosed |
| JP-S57206396-A | PREPARATION OF CYCLIC-3',5'-ADENYLIC ACID BY FERMENTATION METHOD | KIKKOMAN CORP | 1982-12-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207689-A1 | THE TREATMENT OF HEARING LOSS | ADORA1, ADORA2A, ADORA3 | ADA 7/4885ALDH1A1 279/4885TP53 2017/4885 |
| US-20080293665-A1 | Purine Nucleotide Derivatives | CGAS, PDE8A, PDE7A | ADA 24/4885ALDH1A1 3225/4885TP53 3284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.